伴随性疾病和突变,包括单次和多次TET2突变,与慢性骨髓单细胞白血病-A基于人群的研究结果相关
Matilda Kjellander Kynning1, Ebba Westerberg1, Linda Forsell1
1HERM, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
British journal of haematology
|November 25, 2025
概括
TET2突变,特别是多重突变,与慢性髓性单细胞白血病 (CMML) 的更好的生存率有关. 这一发现表明,TET2突变状态应纳入未来的CMML预后模型.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 慢性骨髓单细胞白血病 (CMML) 是一种异质骨髓性恶性瘤.
- 准确的预后模型对于管理CMML患者至关重要.
- 特定基因突变,如TET2在CMML预后中的作用需要进一步阐明.
研究的目的:
- 调查疾病特征,并发症和突变与CMML的整体存活率 (OS) 之间的联系.
- 评估TET2突变的预后意义,包括多击突变,在CMML.
- 开发和验证一个改进的CMML的预后模型.
主要方法:
- 对149名连续的CMML患者的基于人口的队列的分析.
- 对TET2突变 (TET2MT) 与野生类型 (TET2WT) 的评估,包括多击TET2MT.
- 多变量分析包括遗传突变 (TET2MT,RUNX1MT),CMML亚型 (CMML-MP) 和临床因素 (ECOG,输血依赖).
- 预后模型的内部验证和交叉验证,将其与现有的CPSS-Mol得分进行比较.
主要成果:
- 与TET2WT相比,TET2MT与更高的血红蛋白,更少的白细胞瘤和更长的生存时间有关.
- 患有多重TET2MT的患者表现出最有利的结果,乳酸脱酶降低,单细胞化减少.
- 多变量分析确定了TET2MT的数量作为改善OS的独立因素.
- RUNX1MT,CMML-MP,ECOG>0和输血依赖是显著的不良预后因素.
- 开发的预后模型包括TET2MT,RUNX1,CMML-MP,ECOG>0和输血依赖,在预测OS方面表现优于CPSS-Mol.
- 将TET2突变状态添加到CPSS-Mol中也提高了其性能.
结论:
- TET2突变状态,特别是多击TET2MT,定义了一个独特的CMML表型,具有良好的预后.
- TET2突变的数量是CMML整体存活率改善的独立预测指标.
- 开发的预后模型与现有得分相比,表现优越,应考虑临床应用.
更多相关视频
10:33Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
Published on: October 15, 2018
8.6K
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
22.2K
相关概念视频
Mismatch Repair
6.2K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.2K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancers Originate from Somatic Mutations in a Single Cell
14.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.5K
Non-LTR Retrotransposons
13.1K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.1K
